Biopharmaceutical company developing treatments for epilepsy and other neuropsychiatric disorders.
Marinus Pharmaceuticals, Inc. is a dedicated pharmaceutical company specializing in the development and commercialization of innovative treatments for patients afflicted with rare genetic epilepsies and other seizure disorders. One of its key offerings is ZTALMY, an oral suspension designed specifically for managing seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. This product caters to both adult and pediatric populations across various healthcare settings, including acute and chronic care, as well as in-patient and self-administered environments.
At the core of Marinus Pharmaceuticals' research and development efforts is ganaxolone, a promising therapeutic candidate targeting genetic epilepsy disorders such as PCDH19-related epilepsy and tuberous sclerosis complex. Ganaxolone also holds potential applications in treating depressive disorders and Lennox-Gestaut Syndrome, leveraging its action on synaptic and extrasynaptic GABAA receptors for anti-seizure, antidepressant, and anxiolytic effects.
The company has established strategic partnerships to advance its mission, including a license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., underscoring its commitment to leveraging external collaborations to enhance its product portfolio. Marinus Pharmaceuticals also collaborates with Orion Corporation, further bolstering its research and development capabilities in the pharmaceutical industry.
Founded in 2003 and headquartered in Radnor, Pennsylvania, Marinus Pharmaceuticals, Inc. continues to pioneer advancements in the treatment landscape for rare genetic epilepsies and seizure disorders, driven by a steadfast dedication to improving the quality of life for patients worldwide.